ProCE Banner Series

ESR1 Mutations in Metastatic HR+ HER2- Breast Cancer: Testing and Treatment

This presentation offers a comprehensive review of ESR1 mutations in hormone receptor-positive (HR+) HER2-negative metastatic breast cancer, focusing on their role in breast cancer biology, patient outcomes, treatment decision-making, and clinical practice. The session will discuss the role of ESR1 mutations, current guidelines for ESR1 mutation testing and treatment, and the evolving treatment landscape. It will also highlight findings from major clinical trials involving patients with relapsed HR+ HER2-negative metastatic breast cancer, both with and without ESR1 mutations.

Learning Objectives

  • Understand the role of ESR1 mutations in HR+ HER2- metastatic breast cancer biology
  • Review current guidelines for ESR1 mutation testing and treatment, and their clinical importance
  • Summarize the current treatment landscape and recent data updates from key clinical trials in patients with relapsed HR+ HER2- metastatic breast cancer, with or without ESR1 mutations, and discuss their implications for clinical practice and patient outcomes

All Events

ESR1 Mutations in Metastatic HR+ HER2- Breast Cancer: Testing and Treatment

Past Events

January

15

2025

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

January

21

2025

6:15 PM - 6:45 PM Eastern Time (ET)

Virtual

January

30

2025

3:15 PM - 3:45 PM Eastern Time (ET)

Virtual